이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

OptiNose 관리

관리 기준 확인 2/4

OptiNose's CEO는 Ramy Mahmoud, Jan2023 에 임명되었습니다 의 임기는 1.42 년입니다. 총 연간 보상은 $ 2.41M, 26.8% 로 구성됩니다. 26.8% 급여 및 73.2% 보너스(회사 주식 및 옵션 포함). 는 $ 559.14K 가치에 해당하는 회사 주식의 0.34% 직접 소유합니다. 559.14K. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 3 년입니다.

주요 정보

Ramy Mahmoud

최고 경영자

US$2.4m

총 보상

CEO 급여 비율	26.8%
CEO 임기	1.5yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	2.1yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%

Apr 27

There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump

Mar 01

Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price

Dec 28

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%

May 23

The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically

Mar 09

OptiNose's Business Is Thriving While OptiNose Trades At Lower Revenue Multiples Than Peers

Dec 01

OptiNose EPS beats by $0.06, beats on revenue

Nov 05

CEO 보상 분석

Ramy Mahmoud 의 보수는 OptiNose 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$2m	US$647k	-US$35m
Sep 30 2023	n/a	n/a	-US$41m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$1m	US$504k	-US$75m
Sep 30 2022	n/a	n/a	-US$75m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$82m
Dec 31 2021	US$1m	US$504k	-US$82m
Sep 30 2021	n/a	n/a	-US$91m
Jun 30 2021	n/a	n/a	-US$95m
Mar 31 2021	n/a	n/a	-US$97m
Dec 31 2020	US$2m	US$489k	-US$100m
Sep 30 2020	n/a	n/a	-US$101m
Jun 30 2020	n/a	n/a	-US$109m
Mar 31 2020	n/a	n/a	-US$110m
Dec 31 2019	US$1m	US$475k	-US$110m
Sep 30 2019	n/a	n/a	-US$111m
Jun 30 2019	n/a	n/a	-US$108m
Mar 31 2019	n/a	n/a	-US$105m
Dec 31 2018	US$609k	US$451k	-US$107m
Sep 30 2018	n/a	n/a	-US$101m
Jun 30 2018	n/a	n/a	-US$93m
Mar 31 2018	n/a	n/a	-US$81m
Dec 31 2017	US$3m	US$438k	-US$62m

보상 대 시장: Ramy 의 총 보상 ($USD 2.41M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Ramy 의 보상이 증가했습니다.

CEO

Ramy Mahmoud (59 yo)

1.5yrs

테뉴어

US$2,414,265

보상

Dr. Ramy A. Mahmoud, M.D., M.P.H., serves as Chief Executive Officer and Director of OptiNose US Inc. since January 2023. He serves as Chief Executive Officer & Director of OptiNose, Inc. since January 31,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ramy Mahmoud	CEO & Director	1.5yrs	US$2.41m	0.29% $ 440.1k
Michael Marino	Chief Legal Officer & Corporate Secretary	7.5yrs	US$1.32m	0.12% $ 187.9k
Paul Spence	Chief Commercial Officer	1.6yrs	US$664.02k	0% $ 0
Anthony Krick	VP of Finance & Chief Accounting Officer	2.1yrs	데이터 없음	0.0053% $ 8.0k
Jonathan Neely	Vice President of Investor Relations & Business Development	no data	데이터 없음	데이터 없음
Karen Brophy	Chief Human Resources Officer & VP of Human Resources	6.4yrs	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: OPTN 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ramy Mahmoud	CEO & Director	1.5yrs	US$2.41m	0.29% $ 440.1k
Sandra Helton	Independent Director	6.4yrs	US$103.42k	0% $ 0
R. Fletcher	Independent Chairman	2.3yrs	US$120.22k	0% $ 0
Eric Bednarski	Independent Director	2.6yrs	US$88.42k	0% $ 0
Wilhelmus C. Groenhuysen	Independent Director	6.8yrs	US$100.92k	0% $ 0
Tomas Heyman	Independent Director	3.6yrs	US$96.88k	0% $ 0
Kyle Dempsey	Independent Director	2.6yrs	US$90.92k	0% $ 0
Catherine Owen	Independent Director	4yrs	US$89.95k	0% $ 0

3.1yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: OPTN 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

OptiNose 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

OptiNose, Inc., Annual General Meeting, Jun 06, 2024

CEO & Director recently sold US$69k worth of stock

OptiNose, Inc. Approves Board Changes

Optinose Announces Board Changes

CEO & Director recently sold US$53k worth of stock

Optinose Announces Departure of Michele Janis as Acting Chief Financial Officer

Recent updates

OptiNose, Inc. announced that it has received $4.68 million in funding

Consensus estimates of losses per share improve by 12%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

OptiNose, Inc. to Report Q1, 2024 Results on May 14, 2024

OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024

OptiNose, Inc., Annual General Meeting, Jun 06, 2024

Not Many Are Piling Into OptiNose, Inc. (NASDAQ:OPTN) Stock Yet As It Plummets 42%

OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025

New minor risk - Share price stability

Price target increased by 7.1% to US$3.75

Full year 2023 earnings: EPS exceeds analyst expectations

OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024

New minor risk - Share price stability

There's Reason For Concern Over OptiNose, Inc.'s (NASDAQ:OPTN) Massive 32% Price Jump

OptiNose, Inc. to Report Q4, 2023 Results on Mar 07, 2024

CEO & Director recently sold US$69k worth of stock

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology

Forecast to breakeven in 2026

Revenues Working Against OptiNose, Inc.'s (NASDAQ:OPTN) Share Price

New minor risk - Share price stability

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

OptiNose, Inc. Revises Revenue Guidance for the Full Year of 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

OptiNose, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus estimates of losses per share improve by 31%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OptiNose, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Profitability

Price target decreased by 16% to US$3.50

No longer forecast to breakeven

OptiNose, Inc. Approves Board Changes

OptiNose, Inc. (NASDAQ:OPTN) Might Not Be As Mispriced As It Looks After Plunging 29%

Consensus EPS estimates fall by 20%, revenue upgraded

Optinose, Inc. Provides Revenue Guidance for Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

The Consensus EPS Estimates For OptiNose, Inc. (NASDAQ:OPTN) Just Fell Dramatically

Full year 2022 earnings: EPS misses analyst expectations

Optinose Announces Board Changes

CEO & Director recently sold US$53k worth of stock

Optinose Announces Departure of Michele Janis as Acting Chief Financial Officer

No longer forecast to breakeven

OptiNose, Inc. has completed a Follow-on Equity Offering in the amount of $50.008 million.

Consensus revenue estimates fall by 13%

High number of new directors

Price target decreased to US$6.60

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OptiNose, Inc. Provides Revenue Guidance for the Full Year 2022

OptiNose, Inc. Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

OptiNose, Inc. to Report Q3, 2022 Results on Nov 10, 2022

CEO & Director notifies of intention to sell stock

CEO & Director recently sold US$190k worth of stock

High number of new directors

OptiNose, Inc. Provides Revenue Guidance for the Full Year of 2022

OptiNose GAAP EPS of -$0.23 beats by $0.01, revenue of $20.6M misses by $0.9M

OptiNose, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Optinose Announces XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

OptiNose: Potential Winner In Chronic Sinusitis Treatment

Optinose Announces Positive Top-Line Results of Reopen2, Its Second Phase 3 Clinical Trial of Xhance for Treatment of Chronic Sinusitis

OptiNose, Inc. Announces Executive Appointments

Optinose, Inc. Updates Revenue Guidance for 2022

OptiNose, Inc. to Report Q1, 2022 Results on May 12, 2022

OptiNose, Inc., Annual General Meeting, Jun 08, 2022

Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director

OptiNose, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

OptiNose: Underappreciated Potential

OptiNose, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022